SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

ANG Lifesciences India informs about newspaper publication

17 Feb 2023 Evaluate
Pursuant to Regulation 30 & 47 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, ANG Lifesciences India has informed that it enclosed copies of Newspaper Advertisement of the Unaudited Financial Results (Standalone & Consolidated) for the Quarter & Nine months ended on 31-Dec-2022, published in the English Newspaper having nationwide circulation -Business Standard and one in Vernacular Newspaper - Desh Sewak on Wednesday, 16-Feb-2023.

The above information is a part of company’s filings submitted to BSE.

ANG Lifesciences Share Price

33.65 -1.19 (-3.42%)
10-Jul-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1935.25
Dr. Reddys Labs. 1245.50
Cipla 1438.75
Zydus Lifesciences 1150.50
Lupin 2496.05
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: